Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study

  1. Richardson, P.G.
  2. Perrot, A.
  3. San-Miguel, J.
  4. Beksac, M.
  5. Spicka, I.
  6. Leleu, X.
  7. Schjesvold, F.
  8. Moreau, P.
  9. Dimopoulos, M.A.
  10. Huang, J.S.-Y.
  11. Minarik, J.
  12. Cavo, M.
  13. Prince, H.M.
  14. Malinge, L.
  15. Dubin, F.
  16. van de Velde, H.
  17. Anderson, K.C.
Journal:
The Lancet Oncology

ISSN: 1474-5488 1470-2045

Year of publication: 2022

Volume: 23

Issue: 3

Pages: 416-427

Type: Article

DOI: 10.1016/S1470-2045(22)00019-5 GOOGLE SCHOLAR